MannKind (NASDAQ:MNKD) Announces Quarterly Earnings Results, Beats Expectations By $0.05 EPS

MannKind (NASDAQ:MNKD) announced its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.01) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.06) by $0.05, FiscalAI reports. The business had revenue of $101.87 million during the quarter, compared to analysts’ expectations of $107.74 million. During the same period in the prior year, the company posted $0.03 earnings per share. The firm’s revenue was up 24.0% on a year-over-year basis.

Here are the key takeaways from MannKind’s conference call:

• Revenue growth broadened beyond collaborations: Third-quarter revenue rose 24% to $101.9 million, with commercial product revenue roughly doubling to $45 million. Tyvaso DPI royalties increased 12% to $37.5 million, while MannKind said its United Therapeutics agreement is expected to provide more than $1 billion in revenue from 2027 through 2030.
• FUROSCIX ReadyFlow adoption is moving quickly: About 75% of shipments had shifted to ReadyFlow by late October, and the company expects fourth-quarter FUROSCIX sales to roughly match first-half 2026 sales. ReadyFlow’s lower cost of goods could also improve margins as the transition progresses.
• Afrezza’s pediatric launch is gaining traction, but the adult business has underperformed: Pediatric patients now account for about one in four prescriptions, and new-to-brand prescriptions rose nearly 80% sequentially. Management attributed adult weakness partly to reduced promotional support and field-team turnover, and said it plans to refocus resources.
• Management expects a return to profitability: Despite a third-quarter GAAP net loss of $23.2 million, the company expects GAAP and non-GAAP profitability in the fourth quarter and annual profitability in 2027, while continuing to invest in commercial growth.
• Nintedanib DPI advanced, with a longer-term clinical milestone ahead: MannKind reported positive Phase I-B safety and tolerability results and is starting its streamlined Phase II study, with a readout expected in the first half of 2028. The timeline could move faster if the FDA supports adding U.S. sites.

MannKind Stock Performance

Shares of NASDAQ:MNKD traded up $0.14 during midday trading on Friday, hitting $3.90. 4,984,958 shares of the stock were exchanged, compared to its average volume of 3,481,324. The company has a market capitalization of $1.25 billion, a PE ratio of -16.96 and a beta of 1.10. MannKind has a 52-week low of $2.23 and a 52-week high of $6.51. The business’s fifty day simple moving average is $3.55 and its two-hundred day simple moving average is $3.71.

Insider Buying and Selling

In other MannKind news, Director Steven Binder sold 39,051 shares of the company’s stock in a transaction dated Friday, September 25th. The stock was sold at an average price of $3.29, for a total value of $128,477.79. Following the transaction, the director directly owned 713,258 shares of the company’s stock, valued at $2,346,618.82. This represents a 5.19% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 2.60% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the company. HC Wainwright reiterated a “buy” rating on shares of MannKind in a report on Thursday, July 23rd. Wall Street Zen raised shares of MannKind from a “sell” rating to a “hold” rating in a research report on Saturday. Zacks Research upgraded shares of MannKind from a “strong sell” rating to a “hold” rating in a report on Monday, October 5th. Chardan Capital assumed coverage on shares of MannKind in a research report on Monday, October 19th. They set a “buy” rating and a $10.00 price objective on the stock. Finally, Royal Bank Of Canada boosted their price objective on shares of MannKind from $4.75 to $5.00 and gave the company a “sector perform” rating in a research report on Friday. Eight investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $8.33.

MannKind News Roundup

Here are the key news stories impacting MannKind this week:

• Positive Sentiment: Analysts raised price targets. Cantor Fitzgerald lifted its target to $10 from $8 and maintained an “overweight” rating. RBC raised its target to $5 from $4.75, while keeping a “sector perform” rating. Cantor Fitzgerald analyst information RBC price target report
• Positive Sentiment: Longer-term revenue and profitability outlook. MannKind expects its United Therapeutics agreement to generate about $1 billion in revenue from 2027 through 2030, and is targeting profitability in the fourth quarter. United Therapeutics deal and profitability outlook
• Neutral Sentiment: Quarterly results were mixed. MannKind’s revenue rose 24% year over year to $101.87 million, and its reported loss per share was narrower than the consensus estimate. MannKind third-quarter results
• Negative Sentiment: Revenue missed expectations, and the company remained loss-making. Sales of $101.87 million were below analysts’ $107.74 million estimate, while EPS was down from a profit in the year-ago quarter. Q3 loss and revenue miss

MannKind Company Profile

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF).